ES-1801

ES-1801 is a preclinical-stage therapeutic candidate being developed by Eusol Biotech for the treatment of wound repair. Eusol Biotech is a biopharmaceutical company based in Taiwan that focuses on developing innovative drugs for inflammatory diseases and tissue regeneration, often utilizing its proprietary recombinant protein platforms. While specific details regarding the molecular target and mechanism of action for ES-1801 have not been publicly disclosed, the asset is currently undergoing preclinical evaluation to assess its potential in accelerating wound healing processes. It is part of a pipeline that includes other assets targeting similar indications, such as ES-1301 (recombinant Annexin A5).